Literature DB >> 29129452

Long-term humoral immunity induced by CVC1302-adjuvanted serotype O foot-and-mouth disease inactivated vaccine correlates with promoted T follicular helper cells and thus germinal center responses in mice.

Luping Du1, Jin Chen1, Liting Hou1, Xiaoming Yu1, Qisheng Zheng2, Jibo Hou3.   

Abstract

Long-lasting humoral immunity is one of the necessary criteria for a successful vaccine. In our previous study, it was demonstrated that the immunopotentiator CVC1302 could improve the humoral immunity induced by the foot and mouth disease virus (FMDV) killed vaccine (KV) with only one dose. Significantly higher FMDV-specific antibody titers and more persistent antibody responses were observed in pigs receiving CVC1302-adjuvanted KV (KV-CVC1302) than in those inoculated with KV alone. In this study, we show that CVC1302 enhances murine IgG responses to FMDV by promoting a potent T follicular helper cell (TFH) response, which directly controls the magnitude of the germinal center (GC) B cell response. These results indicate a need for studies to assess the capacity of CVC1302 to enhance the efficacy of FMDV KV immunization in pigs, and provide new insights into the development of FMDV vaccines.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CVC1302; FMDV; Germinal center; Long-term humoral response; T follicular helper cell

Mesh:

Substances:

Year:  2017        PMID: 29129452     DOI: 10.1016/j.vaccine.2017.10.094

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Mincle and STING-Stimulating Adjuvants Elicit Robust Cellular Immunity and Drive Long-Lasting Memory Responses in a Foot-and-Mouth Disease Vaccine.

Authors:  Min Ja Lee; Hyundong Jo; Sung Ho Shin; Su-Mi Kim; Byounghan Kim; Hang Sub Shim; Jong-Hyeon Park
Journal:  Front Immunol       Date:  2019-10-29       Impact factor: 7.561

2.  The HSP70-fused foot-and-mouth disease epitope elicits cellular and humoral immunity and drives broad-spectrum protective efficacy.

Authors:  Hyundong Jo; Bong Yoon Kim; So Hui Park; Hyun Mi Kim; Sung Ho Shin; Seong Yun Hwang; Su-Mi Kim; Byounghan Kim; Jong-Hyeon Park; Min Ja Lee
Journal:  NPJ Vaccines       Date:  2021-03-26       Impact factor: 7.344

3.  Pattern-Recognition Receptor Agonist-Containing Immunopotentiator CVC1302 Boosts High-Affinity Long-Lasting Humoral Immunity.

Authors:  Luping Du; Liting Hou; Xiaoming Yu; Haiwei Cheng; Jin Chen; Qisheng Zheng; Jibo Hou
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.